Concord Biotech Ltd approves Q2 FY27 results, with revenue of ₹309.1 crore and net profit of ₹69.6 crore
- Revenue rose 25.1% year on year and 20.0% sequentially; net profit increased 10.3% year on year and 20.6% sequentially.
- Operating margin was approximately 33.8%; no exceptional items were reported.
- November 4, 2026, is the record date for the previously declared 1:1 bonus issue.
- Auditor’s limited-review conclusion was unmodified; certain subsidiary and joint-venture information was not reviewed.
Original Filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd0cf818-7f8e-4df4-a883-13be31abe0a7.pdf